User:Mr. Ibrahem/Tralokinumab

Tralokinumab, sold under the brand names Adtralza and Adbry, is a medication used to treat atopic dermatitis. Specifically it is used for moderate to severe disease which is not controlled by medication applied to the skin. It is given by injection under the skin.

Common side effects include upper respiratory tract infections such as the common cold, reactions at the injection site, and eye pain and redness. Other side effects may include anaphylaxis and angioedema. While there is no evidence of harm in pregnancy, such use has not been well studied. It is a monoclonal antibody which blacks the activity of cytokine interleukin 13.

Tralokinumab was approved for medical use in Europe, the United States, and the United Kingdom in 2021. In the United Kingdom it costs the NHS about £1070 for 600 mg as of 2022. This amount in the United States costs about 3,300 USD.